N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution

Molecular Neurobiology

Volumn 52, Issue 2, 2015, Pages 1034-1042

  Skaper, Stephen D ^a   Facci, Laura ^a   Barbierato, Massimo ^a   Zusso, Morena ^a   Bruschetta, Giuseppe ^b   Impellizzeri, Daniela ^b   Cuzzocrea, Salvatore ^b   Giusti, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Luteolin; Mast cells; Microglia; Neurodegeneration; Neuroinflammation; Neuropathic pain; Neuroprotection; Palmitoylethanolamide; Ultramicronization

Indexed keywords

ANANDAMIDE; CANNABINOID; LUTEOLIN; N OLEOYLETHANOLAMINE; N PALMITOYLETHANOLAMINE 2 PENTADECYL 2 OXAZOLINE; N STEAROYLETHANOLAMINE; PALMIDROL; UNCLASSIFIED DRUG; AMIDASE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; NAAA PROTEIN, HUMAN; NAAA PROTEIN, MOUSE; PALMITIC ACID DERIVATIVE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; GLIA; HOST RESISTANCE; HUMAN; INFLAMMATORY PAIN; MAST CELL; MONOTHERAPY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATIENT COMPLIANCE; PAW EDEMA; SPINAL CORD INJURY; TRAUMATIC BRAIN INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BIOTRANSFORMATION; DEPRESSION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; HOMEOSTASIS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; METABOLISM; NEUROCOGNITIVE DISORDERS; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD INJURIES;

ADMINISTRATION, ORAL; AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ETHANOLAMINES; HOMEOSTASIS; HUMANS; INFLAMMATION; LUTEOLIN; MAST CELLS; NEUROCOGNITIVE DISORDERS; NEUROGLIA; NEUROIMMUNOMODULATION; PALMITIC ACIDS; PARTICLE SIZE; SPINAL CORD INJURIES;

EID: 84940792281     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9253-8     Document Type: Article

References (76)

1. Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140:871–882. doi:10.1016/j.cell.2010.02.029
2. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE (2009) Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69:479–491. doi:10.1111/j.1365-3083.2009.02255.x
3. Myers RR, Campana WM, Shubayev VI (2006) The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today 11:8–20. doi:10.1016/S1359-6446(05)03637-8
4. Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2014) Innate and adaptive immune responses in neurodegeneration and repair. Immunology 141:287–291. doi:10.1111/imm.12233
5. Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17:796–808. doi:10.1038/nm.2399
6. McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126:479–497. doi:10.1007/s00401-013-1177-7
7. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10:43. doi:10.1186/1742-2094-10-43
8. Noriega DB, Savelkoul HF (2014) Immune dysregulation in autism spectrum disorder. Eur J Pediatr 173:33–43. doi:10.1007/s00431-013-2183-4
9. Rivat C, Becker C, Blugeot A, Zeau B, Mauborgne A, Pohl M, Benoliel JJ (2010) Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain 150:358–368. doi:10.1016/j.pain.2010.05.031
10. Peferoen LA, Vogel DY, Ummenthum K, Breur M, Heijnen PD, Gerritsen WH, Peferoen-Baert RM, van der Valk P, Dijkstra CD, Amor S (2015) Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J Neuropathol Exp Neurol 74:48–63. doi:10.1097/NEN.0000000000000149
11. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB (2014) Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 8:112. doi:10.3389/fncel.2014.00112
12. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, Ladner KJ, Bevan AK, Foust KD, Godbout JP, Popovich PG, Guttridge DC, Kaspar BK (2014) Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 81:1009–1023. doi:10.1016/j.neuron.2014.01.013
13. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312. doi:10.1038/nrn3722, 10:43
14. Carson MJ (2002) Microglia as liaisons between the immune and central nervous systems. Functional implications for multiple sclerosis. Glia 40:218–231. doi:10.1002/glia.10145
15. Gao YJ, Ji RR (2010) Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126:56–68. doi:10.1016/j.pharmthera.2010.01.002
16. Engler H, Doenlen R, Engler A, Riether C, Prager G, Niemi MB, Pacheco-López G, Krügel U, Schedlowski M (2011) Acute amygdaloid response to systemic inflammation. Brain Behav Immun 25:1384–1392. doi:10.1016/j.bbi.2011.04.005
17. Perry VH, Holmes C (2014) Microglial priming in neurodegenerative disease. Nat Rev Neurol 10:217–224. doi:10.1038/nrneurol.2014.38
18. Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ (2005) Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 102:11408–11413. doi:10.1073/pnas.0504197102
19. Gilfillan AM, Austin SJ, Metcalfe DD (2011) Mast cell biology: introduction and overview. Adv Exp Med Biol 716:2–12. doi:10.1038/ni1158
20. Lambracht-Hall M, Dimitriadou V, Theoharides TC (1990) Migration of mast cells in the developing rat brain. Dev Brain Res 56:151–159. doi:10.1016/0165-3806(90)90077-C
21. Silverman AJ, Sutherland AK, Wilhelm M, Silver R (2000) Mast cells migrate from blood to brain. J Neurosci 20:401–408
22. Silver R, Curley JP (2013) Mast cells on the mind: new insights and opportunities. Trends Neurosci 36:513–521. doi:10.1016/tins.2013.06.001
23. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, Kishi K, Butterfield J, Dahinden C, Bonnefoy J-Y (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340–343. doi:10.1038/365340a0
24. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB (1986) Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78:1701–1706. doi:10.1172/JCI112765
25. Brenner T, Soffer D, Shalit M, Levi-Schaffer F (1994) Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci 122:210–213. doi:10.1016/0022-510X(94)90300-X
26. Costanza M, Colombo MP, Pedotti R (2012) Mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci 13:15107–15125. doi:10.3390/ijms131115107
27. Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, Sandkühler J (2011) Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain 7:42. doi:10.1186/1744-8069-7-42
28. Leal-Berumen I, Conlon P, Marshall JS (1994) IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 152:5468–5476
29. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML (2010) Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 30:689–702. doi:10.1038/jcbfm.2009.282
30. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 25:1099–1112. doi:10.1016/j.bbi.2011.02.006
31. Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, van Kooten C, Vinters HV (2004) Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 5:213–219
32. Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, Eskin A, Liu PT, Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J, Nguyen C, Cho T, Koo P, Sayre J, Martinez-Maza O, Rosenthal MJ, Wiedau-Pazos M (2010) IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation 7:76. doi:10.1186/1742-2094-7-76
33. Skaper SD, Facci, Giusti P (2014) Mast cells, glia and neuroinflammation: partners in crime? Immunology 141:314–327. doi:10.1111/imm.12170
34. Skaper SD, Giusti P, Facci L (2012) Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 26:3103–3117. doi:10.1096/fj.11-197194
35. Pietrzak A, Wierzbicki M, Wiktorska M, Brzezińska-Błaszczyk E (2011) Surface TLR2 and TLR4 expression on mature rat mast cells can be affected by some bacterial components and proinflammatory cytokines. Mediators Inflamm 427473. doi:10.1155/2011/427473
36. Gasque P, Singhrao SK, Neal JW, Götze O, Morgan BP (1997) Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 150:31–41
37. Kim DY, Hong GU, Ro JY (2011) Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. J Neuroinflammation 8:25. doi:10.1186/1742-2094-8-25
38. Wang M, Wang X, Zhao L, Ma W, Rodriguez IR, Fariss RN, Wong WT (2014) Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina. J Neurosci 34:3793–3806. doi:10.1523/JNEUROSCI.3153-13.2014
39. Tabas I, Glass CK (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 166:166–172. doi:10.1126/science.1230720
40. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP (2013) The resolution of inflammation. Nat Rev Immunol 13:59–66. doi:10.1038/nri3362
41. Piomelli D, Sasso O (2014) Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci 17:164–174. doi:10.1038/nn.3612
42. Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462. doi:10.1124/pr.58.3.2
43. Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280:1874–1894. doi:10.1111/febs.12152
44. Leung D, Saghatelian A, Simon GM, Cravatt BF (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45:4720–4726. doi:10.1021/bi060163l
45. Olusanmi D, Jayawickrama D, Bu D, McGeorge G, Sailes H, Kelleher J, Gamble JF, Shahd UV, Tobyn M (2014) A control strategy for bioavailability enhancement by size reduction: effect of micronisation conditions on the bulk, surface and blending characteristics of an active pharmaceutical ingredient. Powder Technol. doi:10.1016/j.powtec.2014.03.032
46. Rasenack N, Müller BW (2004) Micron-size drug particles: common and novel micronization techniques. Pharm Dev Technol 9:1–13
47. Joshi JT (2011) A review on micronization techniques. J Pharmaceutical Sci Technol 3:651–681
48. Bisrat M, Nyström C (1988) Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions. Int J Pharm 47:223–231
49. Oh DM, Curl RL, Yong CS, Amidon GL (1995) Effect of micronization on the extent of drug absorption from suspensions in humans. Arch Pharm Res 18:427–433
50. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S (2014) Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to non-micronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 11:136. doi:10.1186/s12974-014-0136-0
51. Winter CA, Risley EA, Nuss GW (1962) Carrageenan-induced oedema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111:544–547
52. Radi E, Formichi P, Battisti C, Federico A (2014) Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis. doi:10.3233/JAD-132738
53. Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, Bergamini CM, Zuliani G (2013) Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer's disease. Curr Alzheimer Res 10:365–372. doi:10.2174/1567205011310040003
54. Salim S (2014) Oxidative stress and psychological disorders. Curr Neuropharmacol 12:140–147. doi:10.2174/1570159X11666131120230309
55. Grosso C, Valentão P, Ferreres F, Andrade PB (2013) The use of flavonoids in central nervous system disorders. Curr Med Chem 20:4694–4719. doi:10.2174/09298673113209990155
56. Xu B, Li XX, He GR, Hu JJ, Mu X, Tian S, Du GH (2010) Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats. Eur J Pharmacol 627:99–105. doi:10.1016/j.ejphar.2009.10.038
57. Coleta M, Campos MG, Cotrim MD, Lima TC, Cunha AP (2008) Assessment of luteolin (3',4',5,7-tetrahydroxyflavone) neuropharmacological activity. Behav Brain Res 189:75–82. doi:10.1016/j.bbr.2007.12.010
58. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E (2013) A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation 10:91. doi:10.1186/1742-2094-10-91
59. Crupi R, Paterniti I, Ahmad A, Campolo M, Esposito E, Cuzzocrea S (2013) Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression. CNS Neurol Disord Drug Targets 12:989–1001. doi:10.2174/18715273113129990084
60. Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, Esposito E (2014) Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. CNS Neurol Disord Drug Targets. doi:10.2174/1871527313666140806124322
61. Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D, Cuzzocrea S, Esposito E (2014) Neuroprotective effects of Co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J Neurotrauma. doi:10.1089/neu.2014.3460
62. Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF (2010) Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer’s disease. Brain 133:3699–3723. doi:10.1093/brain/awq258
63. Parra-Damas A, Valero J, Chen M, España J, Martín E, Ferrer I, Rodríguez-Alvarez J, Saura CA (2014) Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages. J Neurosci 34:5776–5787. doi:10.1523/JNEUROSCI.5288-13.2014
64. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, Lepack A, Majik MS, Jeong LS, Banasr M, Son H, Duman RS (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18:1413–1417. doi:10.1038/nm.2886
65. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D (2009) Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 106:20966–20971. doi:10.1073/pnas.0907417106
66. Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, Di Marzo V (2010) Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett 20:1210–1213. doi:10.1016/j.bmcl.2009.11.134
67. Yamano Y, Tsuboi K, Hozaki Y, Takahashi K, Jin XH, Ueda N, Wada A (2012) Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase. Bioorg Med Chem 20:3658–3665. doi:10.1016/j.bmc.2012.03.065
68. Duranti A, Tontini A, Antonietti F, Vacondio F, Fioni A, Silva C, Lodola A, Rivara S, Solorzano C, Piomelli D, Tarzia G, Mor M (2012) N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. J Med Chem 55:4824–4836. doi:10.1021/jm300349j
69. Li Y, Yang L, Chen L, Zhu C, Huang R, Zheng X, Qiu Y, Fu J (2012) Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS One 7:8. doi:10.1371/journal.pone.0043023
70. Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D (2013) Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain 154:350–360. doi:10.1016/j.pain.2012.10.018
71. Vitale R, Ottonello G, Petracca R, Bertozzi SM, Ponzano S, Armirotti A, Berteotti A, Dionisi M, Cavalli A, Piomelli D, Bandiera T, Bertozzi F (2014) Synthesis, structure-activity, and structure-stability relationships of 2-substituted-N-(4-oxo-3-oxetanyl) N-acylethanolamine acid amidase (NAAA) inhibitors. ChemMedChem 9:323–336. doi:10.1002/cmdc.201300416
72. Siegmund SV, Wojtalla A, Schlosser M, Zimmer A, Singer MV (2013) Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations. Biochem Biophys Res Commun 437:48–54. doi:10.1016/j.bbrc.2013.06.033
73. Hoyer FF, Khoury M, Slomka H, Kebschull M, Lerner R, Lutz B, Schott H, Lütjohann D, Wojtalla A, Becker A, Zimmer A, Nickenig G (2014) Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. J Mol Cell Cardiol 66:126–132. doi: 10.1016/j.yjmcc.2013.11.013
74. Skaper SD, Facci L (2012) Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 367:3312–3325. doi:10.1098/rstb.2011.0391
75. Patent application WO 2013121449 A1 (2013) Compositions and methods for the modulation of specific amidases for n-acylethanolamines for use in the therapy of inflammatory diseases. Published August 22
76. Schäfer T, Starkl P, Allard C, Wolf RM, Schweighoffer T (2010) A granular variant of CD63 is a regulator of repeated human mast cell degranulation. Allergy 65:1242–1255. doi:10.1111/j.1398-9995.2010.02350.x